Scientists in Switzerland have discovered a monoclonal antibody that is effective in neutralizing all variants of the SARS-CoV-2 virus, including Delta.
According to Le News, Lausanne University Hospital (CHUV) and the École Polytechnique Fédérale de Lausanne (EPFL) announced this significant finding last week.
Researchers at CHUV and EPFL stated that the newly identified monoclonal antibody targets the spike protein of the SARS-CoV-2 virus and is effective in neutralizing all variants of concern identified to date, including the Delta variant. These spike proteins assist the SARS-CoV-2 virus in attaching to receptors on the surface of host cells.
The new antibody emerged from lymphocytes (immune cells that destroy infected cells) from a Covid-19 patient and is considered the strongest antibody against Covid-19 discovered to date.
École Polytechnique Fédérale de Lausanne. (Photo: Dreamstime)
The findings of the CHUV and EPFL scientists were published in the prestigious journal Cell Reports. (Photo: EPFL)
Moreover, the antibody appears to bind to a non-mutated region in the receptor-binding area of the spike protein. It prevents the spike protein from attaching to cells with ACE2 receptors, which the SARS-CoV-2 virus uses to invade and infect lung cells.
This means that the antibody blocks the virus replication process, allowing the patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism has been demonstrated through tests on mice.
The new antibody provides protection to patients for 4-6 months. This is a promising preventive treatment option for individuals at undefined risk or those who have been vaccinated but are unable to mount an immune response.
CHUV and EPFL are planning to produce a drug containing this antibody. Clinical trials for the drug are expected to begin in late 2022.
Swiss scientists believe that the discovery of this new antibody is a significant step forward in the fight against Covid-19. It opens the door to improving treatment methods for severe cases and enhancing preventive measures, especially for patients with weakened immune systems.
However, this antibody is not intended to replace Covid-19 vaccines, as vaccines remain the most effective way to prevent the SARS-CoV-2 virus.
